Jitendra A Sattigeri, Sachin Sethi, Joseph A Davis, Shahadat Ahmed, Geeta V Rayasam, Balasaheb G Jadhav, Satya M Chilla, Dhrubajyoti Datta, A Gadhave, Vamshi K Tulasi, Tarun Jain, Sreedhara Voleti, Biju Benjamin, Sunitha Udupa, Garima Jain, Yogender Singh, Kona Srinivas, Vinay S Bansal, Abhijit Ray, Pradip K Bhatnagar, Ian A Cliffe
Designing drug candidates exhibiting polypharmacology is one of the strategies adopted by medicinal chemists to address multifactorial diseases. Metabolic disease is one such multifactorial disorder characterized by hyperglycaemia, hypertension and dyslipidaemia among others. In this paper we report a new class of molecular framework combining the pharmacophoric features of DPP4 inhibitors with those of ACE inhibitors to afford potent dual inhibitors of DPP4 and ACE.
April 13, 2017: Bioorganic & Medicinal Chemistry Letters